ArticleBritish journal of haematology2017
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Abstract readClinical Trial, Phase I
In one paragraph
Article in British journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients.BMC cancer · 2023Trial
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.The New England journal of medicine · 2020Trial
- Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.Cancer immunology, immunotherapy : CII · 2018Trial
- Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.Oncoimmunology · 2026Article
- CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review.Biomolecules & biomedicine · 2026Review
- Tumor microenvironment-driven natural killer cell diversity: mechanisms and therapeutic opportunities.Cancer biology & medicine · 2026Review
- NOT-gated chimeric antigen receptor circuits in T and NK cells.Cell systems · 2026Article
- Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026Review
- Article
- CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models.Blood cancer discovery · 2026Article
- Beyond αβ T cells: unlocking the potential of diverse immune cells in CAR modification.Clinical science (London, England : 1979) · 2026Review
- iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.Frontiers in immunology · 2026Review
- HOPX is required for the generation of umbilical cord blood-derived memory-like NK cells induced by three cytokines.Frontiers in immunology · 2026Article
- Glypican-3-Specific CAR NK Cells Co-Secreting IL-15 and IFN-α Have Increased Anti-Tumor Function Versus Hepatocellular Carcinoma In Vitro.International journal of molecular sciences · 2025Article
- Engineered natural killer cells for cancer therapy.Cancer cell · 2025Review
- CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor.Cancer immunology, immunotherapy : CII · 2025Article
- Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia.HemaSphere · 2025Article
- Review
- Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer.Cancer cell international · 2025Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors.
Nina ShahDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Li LiDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Jessica McCartyDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Indreshpal KaurDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Eric YvonDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Hila ShaimDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Muharrem MuftuogluDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Enli LiuDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Robert Z OrlowskiDepartment of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Laurence CooperDepartment of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Dean LeeDepartment of Hematology & Oncology, Nationwide Children's Hospital, Columbus, OH, USA.
Simrit ParmarDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Kai CaoDepartment of Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Catherine SobieiskiInstitute of Human Nutrition, Columbia University, College of Physicians and Surgeons, New York, NY, USA.
Rima SalibaDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Chitra HosingDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0409-5556
Sairah AhmedDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Yago NietoDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Qaiser BashirDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Krina PatelDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Catherine BollardDepartments of Allergy and Immunology and Blood and Marrow Transplantation, Children's National Health System and George Washington University, Washington, DC, USA.
Muzaffar QazilbashDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Richard ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Katy RezvaniDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MSWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3MP4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1MProteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome InhibitorsR01CA194264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2016 to 2020
$1.8MRole of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in MyelomaR01CA184464 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2015 to 2019
$1.8MNCI NIH HHS L30 CA154037NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA184464NCI NIH HHS R01 CA194264NCI NIH HHS U10 CA032102
Abstract
Multiple myeloma (MM) is a disease with known immune dysregulation. Natural killer (NK) cells have shown preclinical activity in MM. We conducted a first-in-human study of umbilical cord blood-derived (CB) NK cells for MM patients undergoing high dose chemotherapy and autologous haematopoietic stem cell transplantation (auto-HCT). Patients received lenalidomide (10 mg) on days -8 to -2, melphalan 200 mg/m
Indexed as
Adoptive TransferAgedAntineoplastic Combined Chemotherapy ProtocolsCell SeparationCombined Modality TherapyFemaleFetal BloodFlow CytometryGraft SurvivalHematopoietic Stem Cell TransplantationHumansKiller Cells, NaturalLenalidomideMaleMelphalanMiddle AgedLenalidomideMelphalanThalidomideautologous transplantcord bloodex vivo expansionmyelomanatural killer
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.